TrialsgrambetaRCTs are beautiful

AURORA 1

2021

Voclosporin for Lupus Nephritis (AURORA 1)

In 357 patients with active lupus nephritis, adding voclosporin to MMF and low-dose steroids increased complete renal response at week 52 compared with placebo.

Result

Efficacy: Complete renal response at week 52OR 2.65 (95% CI 1.64-4.27) · P < 0.0001

Below 1 favours placebo, above 1 favours voclosporin to MMF and low-dose steroids.

Event rates
Absolute difference
18 points
NNT
6

Absolute difference and NNT are derived from the event rates.

Original publication
Subtopic
Lupus nephritis
Design
Phase 3 double-blind RCT
Relevance
Important: one of several pillars.
Source
Rovin BH, et al. Lancet. 2021;397(10289):2070-2080.doi 10.1016/S0140-6736(21)00578-X

Discussion & critique

Led to FDA approval of voclosporin; AURORA 2 showed the benefit sustained over 2 years.

Discussed in podcasts